Asunaprevir NDA Withdrawal Likely To Mean Daclatasvir Delay
This article was originally published in The Pink Sheet Daily
Bristol pulls NDA for its second-generation protease inhibitor, which likely will alter the data needed for approval of its simultaneously filed NS5A inhibitor. Recent approval of daclatasvir in Europe may offer a glimpse at Bristol’s revised U.S. strategy in HCV.
You may also be interested in...
J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.
Merck and Bristol will run a Phase II trial testing daclatasvir, an NS5A replication complex inhibitor, in tandem with MK-5172, Merck’s potentially pan-genotypic protease inhibitor in a non-exclusive partnership in hepatitis C. It’s the second such deal Bristol has signed this month, following an April 5 agreement with Vertex.
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.